In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.

@article{Sonesson2011InVS,
  title={In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.},
  author={Anders Sonesson and Birgitte Buur Rasmussen},
  journal={Basic & clinical pharmacology & toxicology},
  year={2011},
  volume={109 3},
  pages={195-202}
}
The decapeptide degarelix is a novel competitive gonadotropin-releasing hormone receptor antagonist that has been approved for the treatment of advanced prostate cancer by the FDA and the EU authorities. In this study, the interaction of degarelix with human cytochrome P450 (CYP450) enzymes was investigated in vitro. Inhibition of CYP450 was performed in human liver microsomes using documented marker substrates for the CYP450 isozymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 47 references

In vitro and in vivo metabolism of degarelix , a new anti prostate cancer peptide drug

  • A Sonesson, B BuurRasmussen
  • Drugs
  • 2009

Human cytochromes P 450 mediating phenacetin Odeethylation in vitro : validation of the high affinity component as an index of CYP 1 A 2 activity

  • K Venkatakrishnan, DJ Greenblatt
  • Drug Metab Rev
  • 2007

Similar Papers

Loading similar papers…